Research programme: coronavirus vaccines - OSIVAX
Alternative Names: Universal coronavirus vaccine – OSIVAXLatest Information Update: 28 Aug 2024
At a glance
- Originator OSIVAX
- Class COVID-19 vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in France (Parenteral)
- 09 Jul 2020 Early research in COVID-2019 infections (Prevention) in France (Parenteral)
- 09 Jul 2020 Bpifrance and Assistance Publique Hôpitaux de Paris (AP-HP) plans phase I and phase IIa clinical trials